A Cell-Free DNA Biomarker for Diagnosis and Prognosis of Diseases with Degenerative Processes (UCLA Case No. 2023-250)

UCLA researchers led by Professor Noah Zaitlen in the Departments of Computational Medicine and Neurology have developed a cutting-edge platform for leveraging cfDNA molecular signatures as powerful biomarkers, advancing early diagnosis and prognosis in degenerative diseases through a minimally invasive, highly sensitive liquid biopsy method.

INNOVATION: This technology focuses on detecting specific patterns and alterations in cfDNA that are indicative of degenerative diseases, such as neurodegenerative disorders (Alzheimer’s, Parkinson’s), chronic inflammatory diseases, and potentially other progressive tissue-wasting conditions. By analyzing methylation signatures, fragment size profiles, or other molecular characteristics of cfDNA, the method can differentiate cells of origin and provide early disease detection, monitor progression, and predict prognosis.

ADVANTAGES:

• Unlike traditional biomarkers relying on invasive biopsies or imaging, cfDNA allows for minimally invasive liquid biopsies from blood or other biofluids, facilitating easier, repeatable sampling for disease management.
• Potential pre-symptomatic detection and personalized monitoring of disease progression, enabling timely therapeutic intervention to slow or alter the course of degenerative illnesses.
• Using cfDNA biomarkers across multiple degenerative diseases offers a broad clinical utility, from neurodegeneration to musculoskeletal and systemic fibrotic disorders.
• Enabling longitudinal disease monitoring and response prediction.